These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 32151275)

  • 1. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells.
    Masoumi E; Jafarzadeh L; Mirzaei HR; Alishah K; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
    J Exp Clin Cancer Res; 2020 Mar; 39(1):49. PubMed ID: 32151275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
    Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
    Soltantoyeh T; Akbari B; Shahosseini Z; Mirzaei HR; Hadjati J
    Front Immunol; 2024; 15():1362904. PubMed ID: 38855110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.
    Fallah-Mehrjardi K; Mirzaei HR; Masoumi E; Jafarzadeh L; Rostamian H; Khakpoor-Koosheh M; Alishah K; Noorbakhsh F; Hadjati J
    Immunol Lett; 2020 Jul; 223():44-52. PubMed ID: 32289340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
    Giuffrida L; Sek K; Henderson MA; Lai J; Chen AXY; Meyran D; Todd KL; Petley EV; Mardiana S; Mølck C; Stewart GD; Solomon BJ; Parish IA; Neeson PJ; Harrison SJ; Kats LM; House IG; Darcy PK; Beavis PA
    Nat Commun; 2021 May; 12(1):3236. PubMed ID: 34050151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell.
    Jafarzadeh L; Masoumi E; Alishah K; Mirzaei HR; Jamali A; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
    Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):264-275. PubMed ID: 32615660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells.
    Jafarzadeh L; Masoumi E; Mirzaei HR; Alishah K; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Rostamian H; Noorbakhsh F; Hadjati J
    Mol Immunol; 2021 Nov; 139():1-9. PubMed ID: 34450537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.
    Beavis PA; Henderson MA; Giuffrida L; Mills JK; Sek K; Cross RS; Davenport AJ; John LB; Mardiana S; Slaney CY; Johnstone RW; Trapani JA; Stagg J; Loi S; Kats L; Gyorki D; Kershaw MH; Darcy PK
    J Clin Invest; 2017 Mar; 127(3):929-941. PubMed ID: 28165340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
    Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway.
    Li N; Tang N; Cheng C; Hu T; Wei X; Han W; Wang H
    Oncoimmunology; 2020 Sep; 9(1):1824643. PubMed ID: 33457103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
    Front Immunol; 2021; 12():628906. PubMed ID: 33777013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
    Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
    Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule AZD4635 inhibitor of A
    Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
    Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A
    Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
    J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
    Zhu Y; Wang K; Yue L; Zuo D; Sheng J; Lan S; Zhao Z; Dong S; Hu S; Chen X; Feng M
    Pharmacol Res; 2024 May; 203():107186. PubMed ID: 38641176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
    Chu GJ; Bailey CG; Nagarajah R; Liang O; Metierre C; Sagnella SM; Castelletti L; Yeo D; Adelstein S; Rasko JEJ
    Cytotherapy; 2024 Apr; 26(4):325-333. PubMed ID: 38349311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells.
    El-Serafi I; Micallef Nilsson I; Moter A; Duan Z; Mattsson J; Magalhaes I
    Cancer Immunol Immunother; 2024 Jul; 73(9):163. PubMed ID: 38954005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine-A2A Receptor Pathway in Cancer Immunotherapy.
    Sun C; Wang B; Hao S
    Front Immunol; 2022; 13():837230. PubMed ID: 35386701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.